Optimization of Diphtheria Toxoid Absorption on Aluminum Phosphates and its Relationship with Potency

Document Type : Original Article (s)

Authors

1 Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran

2 Associate Professor, Department of Human Vaccine and Antisera, Razi Vaccine and Serum Research Institute, Karaj, Iran

3 Assistant Professor, Department of Human Vaccine and Antisera, Razi Vaccine and Serum Research Institute, Karaj, Iran

4 Assistant Professor, Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran

Abstract

Background: In the mid-1940s, the diphtheria toxoid (inactivated toxin) vaccine was developed via combination with tetanus and pertussis vaccines (DTP vaccine) and successfully conducted to eradication of diphtheria disease throughout the world. Optimization of diphtheria toxoid absorption on aluminum phosphates to improve the rate of absorption and increase the efficacy of vaccine was our aim.Methods: In this study, the effect of different parameters, such as initial pH, temperature and final pH, on the adsorption rate of diphtheria toxoid on aluminum phosphate gel waz studied in vitro and vivo. Purified diphtheria toxoid was used for vaccine preparation. It was adsorbed to aluminum hydroxide with different pH values (5.0, 5.2, 5.4, 5.6, 5.8 and 6.0) and exposed to various temperatures (4, 24 and 37°C) and adjusted to the final pH values of 6.4, 6.6 and 6.8.Findings: The effective formulation was the pH of 5.8 at the temperature of 4°C with the final pH of 6.6.Conclusion: The level of antibody in the immunized animals significantly was high. It is suggested that with new formulated vaccine with the optimized conditions, can significantly make the rate of toxoid and level of antibody high in the immunized animals.

Keywords

References

  1. Rydell N, Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 2004; 22(9-10): 1265-74.
  2. Moro PL, Yue X, Lewis P, Haber P, Broder K. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Vaccine 2011; 29(50): 9404-8.
  3. Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993; 11(9): 914-8.
  4. Lindblad EB. Aluminium adjuvants--in retrospect and prospect. Vaccine 2004; 22(27-28): 3658-68.
  5. Lima KM, dos Santos SA, Rodrigues JM, Silva CL. Vaccine adjuvant: it makes the difference. Vaccine 2004; 22(19): 2374-9.
  6. Aggerbeck H, Heron I. Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I. Vaccine 1995; 13(14): 1360-5.
  7. O'Hagan DT. Preparation methods and research protocols: Mmethods in molecular medicine. New York, NY: Springer; 2000. p. 435-50.
  8. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27(25-26): 3331-4.
  9. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27(1): 49-55.
  10. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82(5): 488-96.
  11. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25(19): 3752-62.
  12. Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Virol 1994; 68(3): 1418-25.
  13. Rimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004; 22(23-24): 3127-35.
  14. Aggerbeck H, Wantzin J, Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations--III. Vaccine 1996; 14(13): 1265-72.
  15. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19(17-19): 2666-72.
  16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193(1): 265-75.
  17. Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N. Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharm J 2011; 19(4): 197-206.
  18. Lyng J. Potency assay of diphtheria and tetanus toxoids some theoretical and practical considerations. Dev Biol Stand 1986; 64: 47-50.
  19. Sivananda N, Sundaran B. Studies on adsorption of diphtheria toxoid on aluminium phosphate gel. Indian Journal of Science and Technology 2010; 3(3): 248-9.
  20. Gupta RK, Siber GR. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine 1995; 13(14): 1263-76.
  21. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998; 32(3): 155-72.
  22. Regnier M, Metz B, Tilstra W, Hendriksen C, Jiskoot W, Norde W, et al. Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant. Vaccine 2012; 30(48): 6783-8.
  23. Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 2014; 28: 1-5.
Journal of Isfahan Medical School
Volume 33, Issue 343 - Serial Number 343
May and June 2015
Pages 1128-1136

Files

History

  • Receive Date: 06 April 2015
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics